MedTrace Logo

Treatment of IgG4-Related Disease With Revlimid and Rituximab

NCT02705638 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-07-08

No results posted yet for this study

Summary

Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?

Conditions

  • Immunoglobulin G Subclass 4 Related Disease
  • IgG4-related Disease
  • Autoimmune Pancreatitis
  • IgG4-related Sclerosing Cholangitis
  • Retroperitoneal Fibrosis

Interventions

DRUG

Rituximab

All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.

DRUG

Lenalidomide

All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Mark D Topazian, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02705638 on ClinicalTrials.gov